NCT07689162 Liposomal Bupivacaine vs Standard Bupivacaine for Post-Rhinoplasty Analgesia
| NCT ID | NCT07689162 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Washington University School of Medicine |
| Condition | Pain, Postoperative |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2026-08-01 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 45 participants in total. It began in 2026-08-01 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to find out which pain medication is more effective in reducing pain after nose surgery (rhinoplasty). The investigators are looking to find the best treatment to reduce discomfort and improve the healing process for patients having nose surgery.
Eligibility Criteria
Inclusion Criteria: * Adult patients (≥18 years) undergoing open rhinoplasty of any indication or complexity (e.g., primary, revision, functional, or cosmetic), including autologous grafting of any type (e.g., septal or costal cartilage) or cadaveric grafting. Exclusion Criteria: * Chronic pain condition requiring ongoing or scheduled analgesic therapy, or any diagnosis associated with chronic pain (e.g., fibromyalgia, chronic headache/migraine, neuropathic pain, complex regional pain syndrome), long-term opioid use (≥3 months, any agent), allergy or contraindication to local anesthetics, acetaminophen, ibuprofen / NSAIDs, tramadol, ketamine, Medrol (methylprednisolone) dose pack * Concurrent non-nasal surgery planned
Contact & Investigator
Matthew Wu, MD
PRINCIPAL INVESTIGATOR
Washington University School of Medicine
Frequently Asked Questions
Who can join the NCT07689162 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pain, Postoperative. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07689162 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07689162 currently recruiting?
Yes, NCT07689162 is actively recruiting participants. Contact the research team at mjwu@wustl.edu for enrollment information.
Where is the NCT07689162 trial being conducted?
This trial is being conducted at St Louis, United States.
Who is sponsoring the NCT07689162 clinical trial?
NCT07689162 is sponsored by Washington University School of Medicine. The principal investigator is Matthew Wu, MD at Washington University School of Medicine. The trial plans to enroll 45 participants.